Current challenges and controversies in the management of chronic spontaneous urticaria

Expert Review of Clinical Immunology

Volumn 11, Issue 10, 2015, Pages 1073-1082

  Asero, Riccardo ^a   Pinter, Elena ^b   Marra, Alessandro Maria ^b   Tedeschi, Alberto ^c   Cugno, Massimo ^d   Marzano, Angelo Valerio ^d  

^a Internal Medicine Department   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

chronic spontaneous urticaria; corticosteroids; cyclosporine; omalizumab

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MIRTAZAPINE; OMALIZUMAB; RITUXIMAB;

CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG RESPONSE; HUMAN; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; ANIMAL; CHRONIC DISEASE; RECURRENT DISEASE; URTICARIA;

ADRENAL CORTEX HORMONES; ANIMALS; CHRONIC DISEASE; CYCLOSPORINE; HUMANS; OMALIZUMAB; PREVALENCE; RECURRENCE; TREATMENT FAILURE; URTICARIA;

EID: 84942098650     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1069708     Document Type: Review

References (78)

1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69: 868-87
2. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007;33:134-43
3. Gaig P, Olona M, Munoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004;14: 214-20
4. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:621-3
5. Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704
6. Hide M, Francis DM, Grattan CEH, et al. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328: 1599-604
7. Tedeschi A, Asero R, Lorini M, et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010;40:875-81
8. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010;5:97-101
9. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: A retrospective analysis. J Investig Allergol Clin Immunol 2010;20:386-90
10. Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: A worldwide perspective. World Allergy Organ J 2012;5:125-47
11. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133:1270-7
12. Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991;25:1065-7
13. Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997;52:312-16
14. Serhat Inaloz H, Ozturk S, Akcali C, et al. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: A clinical and immunological evaluation. J Dermatol 2008;35:276-82
15. Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000;143:365-72
16. Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003;24:285-90
17. Baskan EB, Tunali S, Turker T, Saricaoglu H. Comparison of short-and long-term cyclosporine A therapy in chronic idiopathic urticaria. J Dermatolog Treat 2004;15:164-8
18. Vena GA, Cassano N, Colombo D, Neo-I-30 Study Group. Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55:705-9
19. Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010;65:1478-82
20. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73
21. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35
22. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in chronic idiopathic/ spontaneous urticaria patients symptomatic despite standard combination therapy. J. Allergy Clin. Immunol 2013;132:101-9
23. Tedeschi A, Airaghi L, Lorini M, Asero R. Chronic urticaria: A role for newer immunomodulatory drugs? Am J Clin Dermatol 2003;4:297-305
24. Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study. J Am Acad Dermatol 2005;52:145-8
25. Perez A, Woods A, Grattan CE. Methotrexate: A useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010;162:191-4
26. Sagi L, Solomon M, Baum S, et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol 2011;91: 303-6
27. Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002;89:212-14
28. Asero R. Oral cyclophosphamide in a case of cyclosporine and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol 2005;30:582-3
29. Tedeschi A. Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Eur Ann Allergy Clin Immunol 2009;41:187-9
30. Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006;45:1224-7
31. Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: Experience in 19 patients. J Am Acad Dermatol 2012;66:767-70
32. Hashimoto T, Kawakami T, Ishii N, et al. Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatol Ther 2012;25:379-81
33. O'Donnell BF, Barr RM, Kobza Black A, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138:101-6
34. Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007;39: 237-42
35. Klote MM, Nelson MR, Engler RJ. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005;94:307-8
36. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005;80:41-7
37. Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000;55: 1099-100
38. Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol 2009;123: 510-11
39. Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol 2011;128:1354-5
40. Mallipeddi R, Grattan CE. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 2007;32: 333-4
41. Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007;119: 705-10
42. Asero R, Tedeschi A, Riboldi P, et al. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008;63:176-80
43. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011;66: 428-33
44. Cugno M, Marzano AV, Tedeschi A, et al. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009;148:170-4
45. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000;30: 1161-5
46. Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005;153:216-17
47. Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-dimer: A pilot study. Int Arch Allergy Immunol 2010;152: 384-9
48. Takahagi S, Shindo H, Watanabe M, et al. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate. Acta Derm Venereol 2010;90:425-6
49. Yang JW, Han BG, Kim BR, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668
50. Thormann H, Bindslev-Jensen C. Mirtazapine for chronic urticaria. Acta Derm Venereol 2004;84:482-3
51. Bigata X, Sais G, Soler F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol 2005;53:916-17
52. Boehm I, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy 1999;54:765-6
53. Morgan M, Cooke A, Rogers L, et al. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol Pract 2014;2:601-6
54. Baumgart KW, Mullins R. Use of hydroxychloroquine in refractory urticaria. J. Allergy Clin. Immunol 2000;105:795-6
55. Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004;34:182-6
56. Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003;83:965-1016
57. Wehling M, Lösel R. Non-genomic steroid hormone effects: membrane or intracellular receptors? J Steroid Biochem Mol Biol 2006;102:180-3
58. Tillmann HC, Stuck BA, Feuring M, et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest 2004;34: 67-73
59. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73
60. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9
61. Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice. Expert Opin Biol Ther 2013;13:1225-8
62. Altman MC, Naimi DR. Comment on Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:2528-30
63. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013;110:113-17
64. Sussman G, Hebert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014;112:170-4
65. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. J Dermatol Sci 2014;73:57-62
66. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study. J Invest Dermatol 2015;135:67-75
67. Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337-42
68. Yalcin AD. An overview of the effects of anti-IgE therapies. Med Sci Monit 2014;20: 1691-9
69. Yalcin AD, Celik B, Gumuslu S. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opin Biol Ther 2014;14:283-6
70. Meyer-De, Schmid JJ, Neuman A. Treatment of chronic urticaria with heparin. Bull Soc Fr Dermatol Syphiligr 1952;59: 286-7
71. Eckman JA, Sterba PM, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010;125:889-95
72. Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012;130: 1123-9
73. Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria: supporting or leading actors? World Allergy Organ J 2009;2:213-17
74. Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy 2014;69:683-91
75. Gericke J, Ohanyan T, Church MK, et al. Omalizumab may not inhibit mast cell and basophil activation in vitro. J Eur Acad Dermatol Venereol 2014. [Epub ahead of print]
76. Chan MA, Gigliotti NM, Dotson AL, Rosenwasser LJ. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy 2013;3:29
77. Loria MP, Dambra PP, D'Oronzio L, et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: A therapeutic alternative. Immunopharmacol Immunotoxicol 2001;23:205-13
78. Kasperska-Zajac A. Acute-phase response in chronic urticaria. J Eur Acad Dermatol Venereol 2012;26:665-72